Tracker

← Portfolio

Other biotech · London, UK

Laverock Therapeutics

GEiGS programmable gene silencing for cell therapies · laverocktx.com ↗

Develops gene-control technology for cell and gene therapies, in oncology and genetic medicine. A non-food holding.

Stage

R&D (step 1 of 6)

Preclinical. In-vivo data released in Jun 2026 support moving its lead oncology programme forward. In Sep 2026 it launched in-vivo programmes in solid tumours and genetic medicine.[1] [2]

Revenue

Pre-revenue

Funded by equity and grants, including more than £2.2m of innovation grants in Jun 2026.[3]

Next Move the lead programme toward clinical development.

Agronomics' holding

Fair value
£48k 30 Jun 2026
Portfolio weight
<1% / n/a
Stake
Not disclosed
Invested
£48k since Jun 2022
Multiple
1.00× No change
Per year
0.0% all holdings
Last round
Seed extension 30 Jun 2025 · 16 months ago

Sources[4]

Investments
What Agronomics put in, at the sterling cost it carries
DateCostRound
Jun 2022£48kSeed[4]

Approvals & markets

No approvals reported.

HQ
United Kingdom
Selling in
—

Timeline

  1. Research

    In-vivo programmes in oncology and genetic medicine[2]

    In-vivo CAR-T for solid tumours, and in-vivo gene silencing aimed first at nervous-system and metabolic disorders.

  2. Research

    In-vivo data support solid-tumour programmes[1]

  3. Funding

    More than £2.2m in innovation grants[3]

    To scale its T-cell products and expand beyond oncology.

  4. Research

    Collaboration with ReNeuron[6]

    Pairs Laverock's gene-silencing platform with ReNeuron's exosome delivery to test in-vivo gene targeting. Terms not disclosed.

Sources

  1. In-vivo data support progression of solid tumour programmes Labmate Online · 10 Jun 2026
  2. Laverock Therapeutics announces in vivo programmes in oncology and genetic medicine Laverock Therapeutics · 30 Sep 2026
  3. Laverock Therapeutics awarded in excess of £2.2M in grants for gene-control platform Bionity · Jun 2026
  4. Q2 2026 Investor Report (portfolio at 30 June 2026) Agronomics Limited · 21 Aug 2026
  5. Laverock relocates to Tribeca development in London's Kings Cross, establishing expanded lab facilities to facilitate growth Laverock Therapeutics · 17 Mar 2025
  6. Reneuron and Laverock Therapeutics announce collaboration to develop in-vivo gene therapy approaches Laverock Therapeutics · 7 Jan 2026